ArticleBlood2023
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Abstract read
In one paragraph
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.Annals of hematology · 2026Article
- Cognitive dysfunction associated with cellular immunotherapy for cancer.Neuro-oncology advances · 2026Review
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.Leukemia · 2026Review
- Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.Blood cancer journal · 2026Article
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
- The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy.Therapeutic advances in neurological disorders · 2026Review
- Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.Blood cancer journal · 2025Article
- Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.Nature reviews. Cancer · 2025Review
- Cancer-related movement disorders: A scoping review and diagnostic approach.Neuro-oncology practice · 2025Review
- Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review.Journal of neuro-oncology · 2025Review
- Robust CD4medRxiv : the preprint server for health sciences · 2025Article
- Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.Blood cancer journal · 2025Article
- Neurological complications of CAR T cell therapy for cancers.Nature reviews. Neurology · 2025Review
- Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.Blood advances · 2025Article
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma.Blood cancer journal · 2025Article
- Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.Blood · 2025Article
- Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma.Journal of hematology · 2025Article
- Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.Blood · 2025Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Charlotte E GrahamCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-7874-7305
Won-Ho LeeCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0009-0000-5158-1202
Hadley R WigginCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Valentina M SupperCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-3726-1840
Mark B LeickCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0003-3111-0221
Filippo BirocchiCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-5214-233X
Andrew J YeeDepartment of Medicine, Harvard Medical School, Boston, MA.
Angelina PetrichenkoDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-0600-0709
John EverettDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Hossein SadrzadehCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Otto RapalinoDepartment of Medicine, Harvard Medical School, Boston, MA.ORCID 0000-0002-5038-4183
Daniel ChiuDepartment of Medicine, Harvard Medical School, Boston, MA.
Isabel Arrillaga-RomanyDepartment of Medicine, Harvard Medical School, Boston, MA.
Marcela V MausCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.ORCID 0000-0002-7578-0393
Matthew J FrigaultCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Kathleen M E GallagherCellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.
Funding
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucelR01CA252940 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MAUS, MARCELA VALDERRAMA · 2020 to 2024
$3.4MNCI NIH HHS R01 CA252940
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsMultiple MyelomaCognitionHumansImmunotherapy, AdoptiveAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.